第三届生物制药分离纯化技术学术论坛——嘉宾介绍（四）
前沿的学术交流，强大的演讲嘉宾阵容，丰富的内容涵盖。一个绝对不容错过的知识盛宴——等你而来！
【嘉宾介绍】
Life Science Product Sales, Marketing & Business Development in Asia Pacific
Dealers, Distributor, Key Account & Customer Relations Management
Bioseparations and Protein Purification from Lab to Production Scale
Bioprocess development & cGMP Bioproduction and Process Monitoring
Downstream Processing & Development of Biologics and Vaccines
Pharmaceutical Manufacturing Technologies
Speaker and presenter at more that 30 local and International Seminars and Conferences on Vaccines, Biologics and Plasma Products in the Asia Pacific region and chaired/moderated several sessions, in the past 3 years. Lectured in protein and vaccine purification courses at institutes and universities.
【演讲主题】
Separation technologies in development and production of biotherapeutics
【演讲摘要】
Small molecule drugs will continue to dominate the pharmaceutical market but large biomacromolecule therapeutics are gaining strong momentum amongst biotechnology and pharmaceutical companies. These new biotherapeutics that are being developed rely more and more on large and complex biomacromolecules and even bionanoparticles. They include very large proteins, polymer-protein conjugates, antibodies, plasmid DNA, viruses, virus like particles (VLPs) and cells. These biomacromolecules ranging from a few hundred kDa to thousands of kDaltons and up to hundreds of nanometers in size, pose great challenges to bioseparation technologies
Biomanufacturing technologies and processes, both upstream and downstream, are being redesigned and optimized to cope with the ever-increasing demand for such new biotherapeutics. In downstream processing, liquid chromatography still represents the most powerful tool for separations of biomolecules, relies mostly on conventional particle -based separations and new improved high quality separation media and systems from an increasing number of new manufacturers offer a much wider and economical choice than ever before and
The development separation technologies over the century, it’s current state-of-the art and it’s importance and contribution to present development and production of biotherapeutics in a highly regulated environment , will be presented.
【嘉宾介绍】
Fan Kai, after graduation from Suzhou Medical School and practiced as medical resident for two years, followed M.S and Ph.D study in Cell Biology from Peking Union Medical School. Dr.Fan started his scientific research career as postdoctoral fellow in Wayne State University where he involved in cytokine regulating mechanism on hematopoietic differentiation. Backed to china，he conducted biopharma research and development, and was used to be vice professor in Chongqing Medical University(1996-2000) and professor in Chongqing University of Technology(2004-2013). He founded Fagen Biomedical Company in 2001 and executed preclinical or clinical researches of several biobetter and innovative biodrugs. He is a kind of specialist in developing pegylated proteins or peptides and owns over twenty international and domestic relating patents.
【演讲主题】
Strategy on Separation and Purification of Pegylated Proteins
【演讲摘要】
Pegylation of recombinant proteins or peptides is still-progressing field in biopharmaceutic development and market. Pegylated medicines including interferon, enzyme, cytokine, antibody, peptide, nucleic analog and chemicals have been approved to eliminate immunogenicity and to prolong half-life in vivo and to improve drug stability. However, pegylations with different PEG classes (MW, form and active group) at different sites (mono,di,multi) by different linkages display different strategies on how to separate the demand pegylated protein as design, because pegylations could block or encapsidate the protein or peptide properties utilized for separation and purification.
【嘉宾介绍】
Dr. Wu Chen is a Senior Research Scientist in Columns R&D, Agilent Technologies, Wilmington, Delaware, USA. He received his B. S. degree in Chemistry from University of Science and Technologies of China, Hefei, China, and Ph.D. degree in organic chemistry from Iowa State University, Ames, Iowa. Since 1997, he has been working in Columns R&D in Agilent Technologies. He has developed sub two micron totally porous particles and superficially porous particles in different particle sizes and pore sizes for small molecule and large biomolecule separation in HPLC/UHPLC. He is a HPLC column expert, specializing HPLC column packing material development, silica surface chemistry, phase development, and column packing techniques. He owns more than 10 US patents, and has given a series of presentations at conferences and customer sites.
【演讲主题】
The recent development of superficially porous particles for separation of small molecules and large biomolecules
【演讲摘要】
Superficially porous particle (SPP) technology has been rapidly adopted by chromatographers in the past several years due to its convincing performance advantage over totally porous particles (TPP) such as High efficiency and lower back pressure. Columns using SPPs are currently available in a wide variety of particle sizes, pore sizes and stationary phase chemistries to meet most analysts’ needs. This work will present an overview of current status of SPPs, syntheses of SPPs, and more recent development of expanding family of SPPs with different particle sizes and pore sizes for small molecule and large biomolecule separations, as well as future direction of SPPs. In addition, it will include an innovative hybridized superficially porous particle that is designed to resist degradation in high pH mobile phases. By using this high pH stable SPP column, one can run separation in low, neutral and high pHs as a way to gain different selectivity.
【联系方式】
会务组联系人：
朴京林 0512-62956000-812 pjl@nanomicrotech.com
展商联系人：
马 益 0512-62956000-809 my@nanomicrotech.com
酒店预定联系人：
刘明君 0512-62956000-826 mjliu@nanomicrotech.com
-
焦点事件
